Stenzl - Figure 29
ERBB2 mutations characterize excellent response to NAC
FIG. 29: From the study results shown in this Figure, the presence of ERBB2 mutations appears to predict an excellent response to neoadjuvant chemotherapy.[20] ERBB2 mutations were present only in complete responders to neoadjuvant chemotherapy, whereas none of those mutations was present in the nonresponders. However, there are others (eg, ERCC2 missense mutations or ERBB2 amplifications) that may, together with the ERBB2 mutation, act as a score and may be beneficial in identifying those patients who should be given a checkpoint inhibitor or the classic cisplatin-based chemotherapy in the neoadjuvant setting.
References
Groenendijk FH, de Jong J, Fransen van de Putte EE, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol. 2016;69:384−8 http://dx.doi.org/10.1016/j.eururo.2015.01.014
